Teen Depression Impacts Millions of Families.

Teen depression impacts millions of families each year. For some adolescents, traditional antidepressant treatment may not provide adequate relief.​ NeuroStar® Advanced Therapy is an FDA-cleared, non-invasive adjunct treatment option for adolescents ages 15–21 with major depressive disorder. Clinical data show meaningful improvement and remission rates in teens treated with NeuroStar.*​ If you are exploring options for a teen in your life, schedule a consultation to learn more. #TeenDepression #AdolescentMentalHealth #NeuroStar #DepressionTreatment #MDD #NeuroStarProvider @NeuroStarAdvancedTMS *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. 

Teen depression impacts millions of families each year. For some adolescents, traditional antidepressant treatment may not provide adequate relief.​ NeuroStar® Advanced Therapy is an FDA-cleared, non-invasive adjunct treatment option for adolescents ages 15–21 with major depressive disorder. Clinical data show meaningful improvement and remission rates in teens treated with NeuroStar.*​ If you are exploring options for a teen in your life, schedule a consultation to learn more. #TeenDepression #AdolescentMentalHealth #NeuroStar #DepressionTreatment #MDD #NeuroStarProvider @NeuroStarAdvancedTMS *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. 

Teen depression impacts millions of families each year. For some adolescents, traditional antidepressant treatment may not provide adequate relief.​ NeuroStar® Advanced Therapy is an FDA-cleared, non-invasive adjunct treatment option for adolescents ages 15–21 with major depressive disorder. Clinical data show meaningful improvement and remission rates in teens treated with NeuroStar.*​ If you are exploring options for a teen in your life, schedule a consultation to learn more. #TeenDepression #AdolescentMentalHealth #NeuroStar #DepressionTreatment #MDD #NeuroStarProvider @NeuroStarAdvancedTMS *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment.